China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
BeiGene, Ltd. a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide,…
Read More...
Read More...
